Back to Search
Start Over
A Phase I/II study of vesigenurtacel-l (hs-410) or placebo in combination with Bacillus Calmette-Guérin (BCG) in patients with non-muscle invasive bladder cancer (NMIBC)
- Source :
- Journal for Immunotherapy of Cancer
- Publication Year :
- 2014
- Publisher :
- BioMed Central, 2014.
-
Abstract
- Meeting abstracts Vesigenurtacel-L is an allogeneic cell-based therapeutic cancer vaccine that was selected based on its expression of a range of tumor antigens (surviving, LAGE-1, MAGE-A3, MAGE-A11, PRAME and others) that are known to be expressed amongst a high proportion of primary bladder
- Subjects :
- Pharmacology
Oncology
endocrine system
Cancer Research
medicine.medical_specialty
PRAME
Bladder cancer
business.industry
Immunology
Placebo
medicine.disease
Bioinformatics
Phase i ii
Antigen
Internal medicine
Poster Presentation
medicine
Molecular Medicine
Immunology and Allergy
In patient
Cancer vaccine
Non muscle invasive
business
neoplasms
Subjects
Details
- Language :
- English
- ISSN :
- 20511426
- Volume :
- 2
- Issue :
- Suppl 3
- Database :
- OpenAIRE
- Journal :
- Journal for Immunotherapy of Cancer
- Accession number :
- edsair.doi.dedup.....1b97a54abad3ad17c13a38a781c0c4df